A P revious treatment with mitoxantrone is not a contra-
Which of the following findings in a multiple sclerosis (MS)
p atient should arouse the strongest possible suspicion of an a lternative diagnosis? A Contrast enhancement of the meninges on T1 weighted images. B Contrast enhancing periventricular lesions on T1 weighted images. C Hyperintense lesions in proton-density weighted images of the spinal cord. D Hyperintense cortical lesions on double inversion recovery sequences. E Hypointense lesions on T1 weighted images.
A 20-year-old woman presents with a 2 weeks' history of r educed visual acuity (0.2) of the left eye with pain during eye movements. No additional findings on neurological examination, no previous history of neurological symptoms or complaints. Cerebrospinal fluid (CSF) analysis revealed 10 cells/μl, normal protein and 5 oligoclonal bands present only in CSF.
Other progressive MS from the onset of the progressive phase is similar to that of PPMS patients.
What is, according to current literature, the conversion rate of the radiologically isolated syndrome to MS within 5 years?
A <5% B 6-15% C 30-40% D >50%
Which statement is incorrect?
A A cute disseminated encephalomyelitis (ADEM) is a mono phasic demyelinating disease. B ADEM is more likely than MS to occur in older indivi duals. C In most cases of ADEM an infection or vaccination precedes the neurological symptoms by 1-3 weeks. D Encephalopathic symptoms are typical of ADEM. E ADEM variants can be fulminant and devastating with haemorrhagic lesions.
Answers and comments

Answer 1
A is correct. The diagnosis of MS should be questioned when clinical or laboratory findings are atypical. Contrast enhancing periventricular lesions on T1 weighted images are typical findings in MS patients with active disease. Most new enhancing lesions initially appear hypointense on T1 weighted images due to oedema and early demyelination. In approximately 60% of such lesions the T1 signal gradually returns to isointense after months. The persistent T1-weighted hypointense lesions are called chronic black holes and represent areas of insufficient repair and remyelination [1] [2] [3] [4] [5] [6] [7] [8] [9] . The double inversion recovery sequence (DIR) is a relatively new MRI sequence which was introduced in 1998 and distinguishes better between neocortex and the subcortical white matter by suppressing both the white matter and the CSF signal [10] . On DIR images cortical MS lesions appear hyperintense relative to the surrounding grey matter ( fig. 1 ). Meningeal contrast enhancement is not typical of MS and should prompt suspicion of an alternative diagnosis, e.g., neurosarcoidosis.
Answer 2 B is correct.
This patient fulfils the 2010 revised McDonald criteria [11] for relapsing-remitting MS.
According to these new criteria it is possible to demonstrate dissemination in time with a single MRI if this shows gadolinium enhancing and non-enhancing MS lesions simultaneously. To fulfil this criterion it is necessary that the gadolinium enhancing lesion be not the symptomatic one. In the case presented the patient had optic neuritis and the e nhancing lesion was located in the cerebellum, fulfilling the criteria of dissemination in time. Natalizumab can be administered to patients with prior mitoxantrone treatment. However, the duration of natalizumab treatment, the presence of anti-JCV antibodies in the serum and prior use of immunosuppressants such as mitoxantrone are known risk factors for the development of p rogressive multifocal leukencephalopathy (PML) in MS p atients treated with natalizumab. Patients at lowest risk of developing PML are those who tested negative for anti-JCV antibodies, with an estimated risk of 0.11 per 1000 patients (95% confidence interval 0-0.59). Patients on natalizumab treatment for more than 2 years, prior immunosuppressive treatment and positive anti-JCV antibody status have an e stimated PML risk of 7.8 per 1000 patients (95% con fidence interval 5.2-11.3) [12] [13] [14] . Natalizumab is not only licensed for patients who have failed to respond to therapy with i nterferon beta. It can be used as first line medication in p atients with rapidly evolving severe relapsing-remitting MS, defined by the European Medical Agency as two or more disabling relapses in one year, and with one or more gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared with a previous r ecent MRI [15] . Anti-natalizumab antibodies had the p otential to neutralise natalizumab in vitro. About 9-11% of the patients receiving natalizumab developed antibodies at least once during treatment, 3-5% transiently and 6% persistently. The presence of antibodies was correlated with a higher incidence of infusion-related symptoms, a r eduction in serum concentrations o f natalizumab and r educed efficacy. Anti-natalizumab antibodies should be tested in patients who are not responding to natalizumab or patients with i nfusion-related side effects. If positive, antibody testing should be repeated after 2-3 months. If antibodies to natalizumab persist, treatment should be discontinued [16] [17] [18] .
Answer 4
B is correct.
Fingolimod sequesters lymphocytes in lymph nodes, preventing them from moving from the lymph nodes into the blood. This is the reason why after initiation of fingolimod treatment the blood lymphocyte counts decrease within one month. In the Phase III placebo-controlled trial bradycardia and atrioventricular blocks were the most common serious adverse events in fingolimod-treated patients [19] . These findings are transient and related in most cases to the first dose of the medication. After an unexplained sudden death in a patient within 24 hours of taking fingolimod, the European Medicines Agency started a review of fingolimod's cardiovascular safety in January 2012. Recently, on 20 April 2012, the agency issued new and stronger advice to improve management of the risk of adverse effects on the heart in MS patients on fingolimod. According to these recommendations doctors should not prescribe fingolimod to patients with a history of specified cardiovascular and cerebrovascular diseases or who take heart-rate lowering medication. If fingolimod is considered necessary in these patients, the a dvice of cardiologists should be sought and patients should be monitored at least overnight following the first dose. A ccording to Swissmedic all patients starting fingolimod should undergo an ECG before receiving the first dose, and have blood pressure and pulse measurements every hour, followed by a second ECG six hours afterwards [20] . Macular oedema occurred in less than 1% of the patients and was r eversible after discontinuation of fingolimod. Lower r espiratory tract infections including bronchitis and pneumonia were also more frequent in patients treated with f ingolimod compared with placebo. In up to 12.5% of the patients treated with fingolimod t he transaminases increased to levels three times the upper limit of the normal range or more. However, in all patients these asymptomatic liver enzyme abnormalities returned to normal after discontinuing the drug [19] .
Answer 5
C is correct.
Rituximab is a chimaeric anti-CD20 monoclonal antibody that depletes B cells. It is not licensed for the treatment of MS. Since it possesses demonstrated high efficacy in reducing disease activity in relapsing-remitting MS, rituximab can be used as an off-label treatment option for MS in c ertain clinical scenarios, and a humanised anti-CD20 monoclonal antibody, ocrelizumab, is at a late stage of development for MS treatment. The OLYMPUS trial evaluated the efficacy of rituximab in patients with primary progressive (PP) MS. Using 2:1 randomisation, 439 PPMS patients received two infusions of either 1 g intravenous rituximab or placebo e very 6 months for 2 years. The primary endpoint was the time to confirmed disease progression. Secondary endpoints were the change from baseline to week 96 in T2 lesion volume and total brain volume on MRI scans. Despite an overall negative result, a significant effect on confirmed disease progression was seen in a predetermined subgroup analysis of patients aged below 51 years and with one or more G d-enhancing lesions on the baseline MRI [21] .
Answer 6
Primary progressive (PP) MS, unlike relapsing-remitting MS, often presents at a later age and has an equal gender d istribution. When comparing PPMS with secondary progressive MS, the progression of disability from the onset of the progressive phase is similar [22] [23] [24] . Oligoclonal bands or an elevated IgG index are not mandatory for the diagnosis of PPMS, although it is common. Although not formally mentioned in the revised 2010 McDonald criteria, a CSF e xamination is still strongly recommended to rule out alternative diagnoses. Formally, a patient with one year of d isease progression (retrospectively or prospectively determined), one periventricular and two T2 lesions in the spinal cord would theoretically also qualify for the diagnosis of PPMS.
Answer 7
The widespread use of MRI has led to the unexpected d etection of lesions that appear typical of MS in otherwise asymptomatic patients, the so-called radiologically isolated syndrome (RIS). In a prospective study of 53 women and 17 men with a radiologically isolated syndrome (30 patients with oligoclonal bands in CSF) Lebrun et al. found a clinical conversion rate of 33% during a mean follow-up of 5.2 years [25] .
Answer 8
Acute disseminated encephalomyelitis (ADEM) is a mono phasic condition characterised by multifocal inflammatory demyelinating lesions. ADEM is more common in children than adults. Typically ADEM is associated with r ecent vaccination or infections such as measles or varicella. ADEM can usually be distinguished from MS by a history of prior vaccination or infection and the rapid onset of multifocal symptomatic lesions. Alterations in consciousness and seizures are common in ADEM and rare in MS. Patients with ADEM more frequently have contrast enhancing l esions in comparison to MS and CSF analysis usually shows a more pronounced lymphocytic pleocytosis and more s evere blood-CSF barrier disruption by elevated total protein
